develop
implement
highli
multiplex
molecular
diagnost
test
allow
clinic
microbiolog
laboratori
rapidli
sensit
detect
varieti
pathogen
directli
clinic
specimen
current
us
food
drug
administrationapprov
multiplex
panel
target
multipl
differ
organ
simultan
identifi
common
pathogen
implic
respiratori
viral
gastrointestin
central
nervou
system
infect
review
summar
test
characterist
avail
assay
highlight
advantag
limit
multiplex
technolog
infecti
diseas
discuss
potenti
util
new
test
clinic
practic
abil
simultan
detect
identifi
frequent
caus
infecti
diseas
directli
clinic
specimen
use
patient
care
hospit
infect
control
practic
epidemiolog
studi
varieti
commerci
avail
nucleic
acid
amplif
platform
capabl
target
multipl
microorgan
singl
test
reaction
approach
known
multiplex
increasingli
appli
diagnosi
varieti
differ
infecti
diseas
focu
review
current
us
food
drug
administr
fda
clear
approv
multiplex
polymeras
chain
reaction
pcr
panel
design
aid
diagnosi
respiratori
viru
rv
gastrointestin
gi
central
nervou
system
cn
infect
tabl
respiratori
gi
cn
infect
similar
clinic
sign
symptom
syndrom
often
pathogen
specif
infecti
differenti
diagnosi
broad
histor
make
microbiolog
diagnosi
requir
combin
microscopi
antigen
test
cultur
pathogenspecif
pcr
assay
multiplex
molecular
approach
potenti
simplifi
test
algorithm
laboratori
workflow
well
increas
likelihood
action
diagnosi
miss
multiplex
assay
significantli
increas
diagnost
yield
ie
number
organ
detect
larg
due
fact
target
potenti
pathogen
routin
identifi
tradit
method
addit
multiplex
pcr
gener
sensit
routin
cultur
antigen
detect
limit
current
multiplex
test
detect
potenti
pathogen
neg
panel
result
entir
exclud
infect
furthermor
panelbas
test
tailor
individu
patient
current
platform
offer
option
select
organ
target
test
fdaapprov
panel
microorgan
detect
vari
organ
detect
tabl
turnaround
time
tat
result
consid
moder
high
complex
laboratori
perform
test
must
meet
clinic
laboratori
improv
amend
qualiti
standard
profici
test
qualiti
control
personnel
requir
regul
moder
vs
high
complex
test
differ
personnel
requir
ultim
influenc
whether
individu
laboratori
perform
multiplex
test
test
perform
eg
rapidrespons
laboratori
locat
near
patient
vs
special
molecular
section
main
laboratori
first
larg
multiplex
pcr
panel
infecti
diseas
target
respiratori
virus
fda
approv
sinc
multipl
rv
panel
fda
approv
tabl
assay
intend
use
nasopharyng
np
swab
clinic
laboratori
may
also
valid
specimen
type
bronchoalveolar
lavag
fluid
nasal
washesaspir
run
offlabel
test
lower
respiratori
tract
specimen
requir
confirm
whether
viru
detect
np
sampl
also
caus
lower
respiratori
tract
addit
test
lower
tract
specimen
may
indic
despit
neg
nasal
result
clinic
suspicion
viral
pneumonia
high
variou
commerci
avail
rv
panel
compar
one
anoth
laboratorydevelop
monoplex
pcr
signific
sensit
differ
observ
adenoviru
influenza
viru
detect
particular
recent
compar
studi
report
sensit
differ
influenza
target
rang
influenza
b
across
variou
platform
essenti
laboratorian
clinician
understand
perform
characterist
member
panel
well
recogn
preval
individu
pathogen
given
patient
popul
affect
predict
valu
test
potenti
falseposit
result
pcr
amplicon
carryov
contamin
major
concern
highcomplex
platform
involv
manipul
amplifi
pcr
product
even
fulli
integr
close
system
potenti
contamin
raw
specimen
virus
shed
respiratori
tract
oper
laboratori
must
care
follow
oper
procedur
design
minim
contamin
specimen
work
surfac
equip
major
challeng
test
perform
outsid
dedic
molecular
diagnost
section
near
patient
test
consider
given
manipul
specimen
biolog
safeti
cabinet
clean
kept
separ
posit
control
materi
minimum
wear
mask
face
shield
consid
specimen
process
laboratori
also
monitor
posit
rate
individu
target
way
quickli
detect
potenti
contamin
problem
despit
year
experi
rv
panel
rel
data
clinic
impact
multiplex
test
previou
rv
diagnost
studi
shown
rapid
direct
fluoresc
antibodi
stain
np
specimen
shorten
length
hospit
stay
minim
ancillari
test
reduc
unnecessari
antibiot
use
pediatr
patient
advantag
moresensit
molecular
test
detect
broader
spectrum
potenti
pathogen
inpati
pediatr
cost
analysi
assess
price
hospit
admiss
time
respiratori
isol
antibiot
usag
diagnost
procedur
conclud
multiplex
pcr
test
least
expens
test
strategi
long
preval
rv
diseas
multiplex
panel
test
may
also
costeffect
children
influenzalik
ill
evalu
emerg
depart
contrast
pediatr
studi
hospit
adult
patient
suspect
lower
respiratori
tract
infect
receiv
antibiot
even
viru
detect
concern
bacteri
coinfect
approach
lead
overus
antibiot
potenti
unnecessari
drug
toxic
comprehens
molecular
test
viral
bacteri
pathogen
sputum
significantli
increas
likelihood
make
etiolog
diagnosi
communityacquir
pneumonia
cap
howev
current
fdaapprov
molecular
test
typic
bacteri
cap
pathogen
altern
strategi
combin
rv
multiplex
test
result
cultur
urin
pneumococc
legionella
antigen
go
forward
combin
rv
panel
result
serum
biomark
andor
measur
host
immun
respons
may
hold
promis
rule
viral
infect
recent
exampl
util
multiplex
test
epidemiolog
enteroviru
outbreak
occur
summer
hospit
kansa
citi
chicago
notifi
center
diseas
control
prevent
cdc
due
verigen
detect
report
shigalik
toxin
gene
separ
increas
sever
respiratori
ill
among
children
citi
respiratori
specimen
initi
test
posit
rhinovirusenteroviru
identifi
virus
etiolog
agent
diseas
possibl
clinic
laboratori
use
multiplex
panel
routin
patient
test
use
multiplex
molecular
panel
detect
gi
pathogen
also
hot
area
commerci
product
develop
recent
year
gi
assay
design
detect
subset
parasit
bacteria
wherea
other
combin
bacteri
viral
target
target
broader
combin
syndrom
panel
tabl
variou
platform
differ
tat
even
timeintens
assay
hour
significantli
faster
stool
cultur
day
rapid
multiplex
test
compar
convent
method
one
major
advantag
molecular
test
avail
evid
suggest
analyt
perform
current
gi
panel
essenti
equival
analyt
specif
exceed
target
rare
except
sensit
characterist
variabl
howev
valu
rang
sensit
differ
may
due
part
low
preval
individu
pathogen
studiesa
situat
singl
miss
organ
detect
dramat
affect
calcul
target
test
perform
also
import
recogn
lack
robust
diagnost
gold
standard
use
compar
test
multiplex
panel
studi
exampl
multipl
gi
studi
observ
signific
proport
multiplex
pcr
campylobacterposit
cultur
monoplex
pcror
dna
sequencingneg
stool
specimen
import
consider
campylobact
cultur
insensit
analyt
sensit
arbitr
pcr
andor
nucleic
acid
sequenc
poorli
defin
like
mani
multiplex
campylobact
dna
detect
true
posit
given
high
specif
assay
similar
though
less
dramat
trend
seen
target
across
multipl
platform
includ
salmonella
shigellaenteroinvas
escherichia
coli
shigalik
toxinproduc
e
coli
clinician
typic
formul
discret
list
pathogen
top
differenti
diagnosi
multiplex
panel
may
may
detect
organ
potenti
challeng
come
patient
test
posit
clostridium
difficil
exampl
simpli
includ
panel
necessarili
organ
caus
agent
diseas
increas
incid
communityacquir
c
difficil
infect
identif
target
stool
symptomat
outpati
may
difficult
interpret
children
year
age
colon
toxigen
c
difficil
clinic
diseas
age
group
rare
laboratori
implement
gi
panel
test
c
difficil
toxin
ab
target
consid
posit
result
report
infant
children
laboratori
may
choos
releas
result
potenti
use
disclaim
report
healthcar
provid
also
need
interpret
signific
unexpect
detect
sapoviru
enteroaggreg
enteropathogen
e
coli
exampl
organ
routin
identifi
clinic
laboratori
past
prolong
shed
gi
pathogen
also
present
potenti
conundrum
salmonella
noroviru
excret
stool
week
month
symptom
resolv
children
may
asymptomat
infect
cryptosporidium
giardia
lamblia
prolong
shed
event
could
complic
acut
diagnosi
enteropathogen
detect
recent
studi
shown
gi
panelposit
specimen
contain
potenti
pathogen
clinic
implic
coinfect
specif
pathogen
combin
defin
nuanc
forc
clinician
laboratorian
evalu
panel
result
care
context
host
season
unexpect
organ
detect
also
provid
uniqu
opportun
expand
understand
rare
pathogen
season
outbreak
clinic
trial
one
comprehens
gi
panel
investig
iowa
nebraska
detect
cyclospora
cayetanensi
multipl
patient
specimen
well
advanc
outbreak
recogn
laboratori
employ
classic
methodolog
convent
microbiolog
test
evalu
diarrheal
ill
histor
view
low
cost
thu
threshold
order
stool
cultur
stool
antigen
andor
ova
parasit
examin
low
despit
limit
clinic
util
acut
care
set
given
differ
cost
newer
rapid
molecular
test
vs
tradit
method
institut
consid
case
acut
diarrhea
immedi
candid
molecular
gi
test
outpati
set
clinician
think
impact
posit
neg
test
result
patient
care
especi
ill
may
selflimit
inpati
side
goldenberg
colleagu
calcul
potenti
cost
save
hospit
reduct
unnecessari
isol
practic
increas
laboratori
expens
vs
convent
method
although
gi
panel
may
replac
tradit
test
certain
situat
still
need
maintain
cultur
capabl
repeat
test
molecular
test
neg
clinic
suspicion
high
isol
suscept
test
exampl
routin
suscept
test
indic
typhoid
salmonella
shigella
isol
intestin
sourc
isol
submiss
cultur
isol
ill
patient
public
health
laboratori
phl
type
help
identifi
cluster
diseas
caus
bacteri
pathogen
e
coli
salmonella
listeria
work
cdc
associ
public
health
laboratori
american
societi
microbiolog
publish
interim
recommend
new
era
cultureindepend
test
recommend
includ
contact
phl
prior
implement
molecular
test
continu
obtain
isol
much
possibl
clinic
laboratori
unabl
cultur
isol
origin
nucleic
acid
testposit
specimen
submit
transport
medium
within
hour
octob
fda
clear
first
fulli
autom
multiplex
pcr
panel
cn
pathogen
filmarray
mening
enceph
panel
biofir
diagnost
test
bacteri
viral
yeast
pathogen
use
sampl
cerebrospin
fluid
csf
hour
bacteria
yeast
pathogen
identifi
panel
list
tabl
publish
report
evalu
test
perform
panel
largest
prospect
studi
enrol
residu
csf
specimen
design
support
compani
k
submiss
fda
cultur
use
diagnost
gold
standard
bacteri
target
comparison
monoplex
pcr
assay
follow
bidirect
sequenc
use
virus
yeast
discrep
across
method
resolv
repeat
molecular
test
possibl
combin
blind
review
avail
medic
record
adjud
discord
result
posit
neg
agreement
panel
convent
method
sever
import
messag
evid
report
leber
colleagu
first
rel
case
bacteri
cryptococc
mening
preclud
statist
signific
assess
target
previou
report
observ
cryptococcu
target
less
sensit
antigen
test
panel
limit
detect
order
colonyform
unitsml
next
mani
falseposit
unconfirm
panel
result
n
addit
confirm
detect
n
made
comprehens
panel
author
hypothes
contamin
could
play
role
falseposit
panel
result
either
posit
control
materi
normal
flora
test
oper
test
system
close
ie
likelihood
amplicon
carryov
low
like
rv
panel
environment
contamin
still
possibl
laboratori
must
work
dilig
prevent
monitor
also
import
note
studi
subject
necessarili
high
pretest
probabl
infecti
meningoenceph
would
also
reduc
pretest
probabl
diseas
case
last
detect
latent
reactiv
herpesvirida
uncommon
signific
identif
must
evalu
context
patient
avail
data
suggest
panel
test
perform
accept
patient
care
test
replac
current
routin
test
csf
gram
stain
remain
critic
interpret
pcr
result
bacteri
cultur
requir
detect
organ
cover
panel
well
isol
suscept
test
furthermor
cryptococc
antigen
fungal
cultur
remain
prefer
method
diagnos
cryptococc
mening
panel
detect
potenti
pathogen
falseneg
result
possibl
patient
high
clinic
suspicion
bacteri
mening
herp
enceph
still
receiv
empir
therapi
even
panel
neg
potenti
advantag
disadvantag
larg
multiplex
panel
infecti
diseas
summar
tabl
assay
substanti
increas
abil
detect
potenti
pathogen
varieti
differ
clinic
specimen
furthermor
moderatecomplex
platform
enabl
mani
clinic
laboratori
perform
molecular
diagnost
test
inhous
substanti
improv
tat
rel
convent
method
multiplex
molecular
capabl
also
come
sever
import
caveat
new
test
fda
approv
necessarili
mean
right
test
patient
multiplex
reagent
instrument
expens
pretest
probabl
infect
differ
significantli
accord
patient
age
host
immunocompet
time
year
geograph
region
absenc
costeffect
data
recommend
follow
target
approach
panel
test
rv
panel
highest
potenti
impact
immunocompromis
patient
critic
ill
patient
hospit
children
gi
panel
primarili
use
case
dysenteri
moder
sever
diseas
symptom
last
week
immunocompromis
host
communityonset
symptom
panel
target
pathogen
problemat
immunocompromis
patient
test
may
also
speed
time
diagnosi
clinic
suspicion
bacteri
mening
high
patient
alreadi
receiv
antibiot
outsid
select
scenario
laboratori
consult
accept
criteria
base
part
elev
csf
cell
count
consid
immunocompet
adult
way
limit
unnecessari
test
highli
multiplex
molecular
diagnost
power
tool
patient
care
epidemiolog
studi
potenti
infect
control
highli
like
panel
test
increasingli
use
clinic
microbiolog
futur
howev
assay
replac
cultur
addit
test
organ
includ
panel
requir
case
isol
microorgan
still
requir
perform
phenotyp
antimicrobi
suscept
test
provid
isol
public
health
investig
optim
use
larg
panel
infecti
diseas
establish
clinic
util
outcom
studi
ultim
requir
determin
whether
syndrom
diagnost
approach
costeffect
ideal
random
trial
conduct
determin
potenti
impact
rapid
comprehens
molecular
diagnost
test
outcom
interest
includ
antimicrobi
use
time
optim
therapi
length
hospit
emerg
depart
stay
mortal
cost
howev
prospect
studi
may
feasibl
due
prohibit
cost
time
requir
accru
enough
patient
rare
diseas
eg
meningoenceph
implement
research
costeffect
decis
analys
could
also
provid
valuabl
inform
help
guid
ration
use
technolog
meantim
essenti
local
implement
panel
test
done
partnership
clinician
assur
clear
understand
test
characterist
result
interpret
appropri
util
consult
clinic
laboratori
also
use
help
interpret
unexpect
confus
result
